CN1806831A - Medicine for treating psoriasis and its preparing process - Google Patents
Medicine for treating psoriasis and its preparing process Download PDFInfo
- Publication number
- CN1806831A CN1806831A CN 200510009625 CN200510009625A CN1806831A CN 1806831 A CN1806831 A CN 1806831A CN 200510009625 CN200510009625 CN 200510009625 CN 200510009625 A CN200510009625 A CN 200510009625A CN 1806831 A CN1806831 A CN 1806831A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- kaempferol
- epoxy
- glucopyanosyl base
- column chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed is a medicament for treating psoriasis and its preparing process, which comprises: (1) drying datura flower and disintegrating into coarse powder, (2) extracting datura flower coarse powder 3-4 times through 60-70% ethanol backflow, filtering, merging the filter liquor, (3) reclaiming ethanol from filtrate through decompression to make thick grease to obtain ethanol extract, (4) charging the ethanol extract into 0.1-0.5% hydrochloric acid for lixiviating, (5) passing through cationic ion-exchange resin column chromatography effluent liquid and macropore resin column chromatography, (6) washing the effluent liquid to neutral, ethanol eluting, and finally subjecting the eluent to decompressed reclamation.
Description
Technical field
The present invention relates to the extraction of Chinese herbal medicine, Flos Daturae extract and preparation method thereof is used for psoriatic treatment specifically.
Background technology
The Flos Daturae physiologically active is stronger, and medicinal history is long, uses very extensively, is the Chinese medicine of China.Its nature and flavor suffering, temperature, poisonous have the effect of antiasthmatic-antitussive, analgesia spasmolytic, anesthesia.Cure mainly diseases such as asthma and cough, rheumatic arthralgia, coldness and pain in the epigastrium, children's's intermittent infantile convulsion, skin infection pain and as surgical operation anesthetis.Recently clinically Flos Daturae is made the injection for treating psoriasis obtained significant curative effect, but the Flos Daturae injection psoriaticly exists blurred vision, intraocular pressure to raise in treatment simultaneously, heart rate is accelerated, dizzy, xerostomia and untoward reaction such as weak.So, be necessary that Flos Daturae is treated psoriatic effective site to be extracted, and reduces the generation of its untoward reaction.
Summary of the invention
The objective of the invention is to overcome the weak point that exists in the above-mentioned technology, provide a kind of Flos Daturae extract to treat the extraction process of psoriatic effect and effective site thereof.
In order to achieve the above object, the technical solution used in the present invention is:
A, get Flos Daturae and carry out drying, pulverize and be coarse powder;
B, with the Flos Daturae coarse powder with the ethanol of 60-70%, 3-4 each reflux extracting time of reflux, extract, is 2-5 hour, filtration then, merging filtrate;
C, with decompression filtrate recycling ethanol to the thick paste shape, ethanol extraction;
D, ethanol extraction is added the hydrochloric acid lixiviate of 0.1-0.5% again;
E, liquid in-out is iced in acid carried out the cation exchange resin column chromatography effluent and carry out macroporous resin column chromatography again;
Wash with water to effluent after f, the absorption fully and be neutral, use ethanol elution, must active princlple after the eluent reclaim under reduced pressure.
Advantage of the present invention is:
The natural plant that the present invention selects for use is a raw material, extracts making, and it is remarkable to be used for the treatment of the psoriasis effect, nontoxic to human body, meets national pharmaceutical control law regulation.
The specific embodiment
Below embodiments of the invention are described in further detail.
A, get Flos Daturae and carry out drying, pulverize and be coarse powder;
B, with the Flos Daturae coarse powder with the ethanol of 60-70%, 3-4 each reflux extracting time of reflux, extract, is 2-5 hour, filtration then, merging filtrate;
C, with decompression filtrate recycling ethanol to the thick paste shape, ethanol extraction;
D, ethanol extraction is added the hydrochloric acid lixiviate of 0.1-0.5% again;
E, liquid in-out is iced in acid carried out the cation exchange resin column chromatography effluent and carry out macroporous resin column chromatography again;
Wash with water to effluent after f, the absorption fully and be neutral, use ethanol elution, must active princlple after the eluent reclaim under reduced pressure.
Flos Daturae treatment psoriasis active princlple contains 1 effective part group and (comprises that flavone compound is mainly 3-O-β-D-glucopyanosyl base (1 → 2)-β-D-glucopyanosyl base, 7-O-α-L-Fructus rhamni (Rhamnus davurica Pall.) pyrans glycosyl-kaempferol, 3-O-β-D-glucopyanosyl base (1 → 2)-β-D-glucopyanosyl base-kaempferol, 7-O-α-L-Fructus rhamni (Rhamnus davurica Pall.) pyrans glycosyl-kaempferol and 7-O-α-D-glucopyanosyl base-kaempferol), the flavone total content is greater than 50%.Simultaneously, also contain 5 α, 27-dihydroxy-6 α, 7 α-epoxy-1-ketone-2, the liquor-saturated eggplant lactone of 24-diene-27-O-β-D-pyranglucoside (55 α, 27-dihydroxy-6 α, 7 α-epoxy-1-oxowitha-2,24-dienolide-27-O-β-D-glctocopyranoside) (1) and 5 α, 12 α, 27-trihydroxy-6 α, 7 α-epoxy-1-ketone-2, the liquor-saturated eggplant lactone of 24-diene-27-O-β-D-pyranglucoside (5 α, 12 α, 27-trihydroxy-6 α, 7 α-epoxy-1-oxowitha-2, liquor-saturated eggplant lactone glycoside compounds such as 24-dienolidi-27-O-β-D-glctocopyranoside).
This active component can be made into certain dosage form with suitable pharmaceutic adjuvant, as several formulations such as capsule, tablet, granule, injection.
Described drug extract can be treated psoriasis and various dermatosis thereof.
Most preferred embodiment of the present invention
With exsiccant Flos Daturae 10Kg,, add 40 times of amounts with 70% alcohol reflux 3 times at every turn, extract 2.5h/ time, extracting solution pushes back receipts, adds 0.1% hydrochloric acid lixiviate, each consumption is heavy 100 times of cream, lixiviate 8 times, 732 type cationic resin on the sour water leachate, flow velocity 2Br/h, AB-8 macroporous resin on the effluent, flow velocity 1.5Br/h, after the absorption fully, wash with water to effluent neutrality,, get effective site dry powder 40g after the eluent reclaim under reduced pressure with 10 times of amounts of 50% ethanol volume eluting.
Flos Daturae extract experiment showed, mice 2.6,5.2,10.4mg/kg oral administration through main pharmacodynamics, successive administration 3 days, and xylol induced mice ear swelling has the obvious suppression effect.Rat by 1.84,3.68, the 7.36mg/kg oral administration, successive administration 2 days has tangible antagonism to rat paw edema due to the Ovum Gallus domesticus album.More than two experimental results show that Flos Daturae extract has tangible antiinflammatory action.Cavia porcellus 1.6,3.2,6.4mg/kg oral administration, guinea pig skin pruritus due to the histamine phosphate there is the obvious suppression effect, and but significant prolongation shows that by the incubation period of the Cavia porcellus abnormality asthma due to the equivalent mixed liquor of acecoline and histamine phosphate it has antianaphylactic effect.In addition, mice by 2.6,5.2, the 10.4mg/kg oral administration, successive administration 9 days does not all have obvious influence to mice hemolysin content and the cell transformation of mice body endolymph.
Claims (4)
1. treat psoriatic medicine and Therapeutic Method thereof for one kind, it is characterized in that:
A, get Flos Daturae and carry out drying, pulverize and be coarse powder;
B, with the Flos Daturae coarse powder with the ethanol of 60-70%, 3-4 each reflux extracting time of reflux, extract, is 2-5 hour, filtration then, merging filtrate;
C, with decompression filtrate recycling ethanol to the thick paste shape, ethanol extraction;
D, ethanol extraction is added the hydrochloric acid lixiviate of 0.1-0.5% again;
E, liquid in-out is iced in acid carried out the cation exchange resin column chromatography effluent and carry out macroporous resin column chromatography again;
Wash with water to effluent after f, the absorption fully and be neutral, use ethanol elution, must active princlple after the eluent reclaim under reduced pressure.
2. psoriatic medicine of treatment according to claim 1 and Therapeutic Method thereof, it is characterized in that: Flos Daturae treatment psoriasis active princlple contains 1 effective part group and (comprises that flavone compound is mainly 3-O-β-D-glucopyanosyl base (1 → 2)-β-D-glucopyanosyl base, 7-O-α-L-Fructus rhamni (Rhamnus davurica Pall.) pyrans glycosyl-kaempferol, 3-O-β-D-glucopyanosyl base (1 → 2)-β-D-glucopyanosyl base-kaempferol, 7-O-α-L-Fructus rhamni (Rhamnus davurica Pall.) pyrans glycosyl-kaempferol and 7-O-α-D-glucopyanosyl base-kaempferol), the flavone total content is greater than 50%.Simultaneously, also contain 5 α, 27-dihydroxy-6 α, 7 α-epoxy-1-ketone-2, the liquor-saturated eggplant lactone of 24-diene-27-O-β-D-pyranglucoside (55 α, 27-dihydroxy-6 α, 7 α-epoxy-1-oxowitha-2,24-dienolide-27-O-β-D-glctocopyranoside) (1) and 5 α, 12 α, 27-trihydroxy-6 α, 7 α-epoxy-1-ketone-2, the liquor-saturated eggplant lactone of 24-diene-27-O-β-D-pyranglucoside (5 α, 12 α, 27-trihydroxy-6 α, 7 α-epoxy-1-oxowitha-2, liquor-saturated eggplant lactone glycoside compounds such as 24-dienolidi-27-O-β-D-glctocopyranoside).
3. psoriatic medicine of treatment according to claim 1 and 2 and Therapeutic Method thereof is characterized in that: this active component can be made into certain dosage form with suitable pharmaceutic adjuvant, as several formulations such as capsule, tablet, granule, injection.
4. according to claim 1 or psoriatic medicine of 3 described treatments and Therapeutic Method thereof, it is characterized in that: described drug extract can be treated psoriasis and various dermatosis thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510009625 CN1806831B (en) | 2005-01-18 | 2005-01-18 | Medicine for treating psoriasis and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510009625 CN1806831B (en) | 2005-01-18 | 2005-01-18 | Medicine for treating psoriasis and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1806831A true CN1806831A (en) | 2006-07-26 |
| CN1806831B CN1806831B (en) | 2010-04-28 |
Family
ID=36839041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510009625 Active CN1806831B (en) | 2005-01-18 | 2005-01-18 | Medicine for treating psoriasis and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1806831B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102608253A (en) * | 2012-04-09 | 2012-07-25 | 匡海学 | Quality control method of Chinese medicinal hindu datura flower capsule for treating psoriasis |
| CN105503989A (en) * | 2014-09-25 | 2016-04-20 | 赵军 | Method for extraction separation of withanolides compound from waste Chinese wolfberry branches |
| CN108379390A (en) * | 2018-05-14 | 2018-08-10 | 黑龙江中医药大学 | A kind of pharmaceutical composition and its preparation method and application prevented and/or treat psoriasis |
| CN115645470A (en) * | 2022-10-18 | 2023-01-31 | 广西科技大学 | Anti-psoriasis extract of datura flower, preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1073849C (en) * | 1997-05-12 | 2001-10-31 | 孙长柱 | Chinese and western medicine capsule for curing psoriasis and leucodermia in sleep |
-
2005
- 2005-01-18 CN CN 200510009625 patent/CN1806831B/en active Active
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102608253A (en) * | 2012-04-09 | 2012-07-25 | 匡海学 | Quality control method of Chinese medicinal hindu datura flower capsule for treating psoriasis |
| CN102608253B (en) * | 2012-04-09 | 2017-06-16 | 匡海学 | A kind of detection method of the Chinese medicine datura flower capsule for treating psoriasis |
| CN105503989A (en) * | 2014-09-25 | 2016-04-20 | 赵军 | Method for extraction separation of withanolides compound from waste Chinese wolfberry branches |
| CN108379390A (en) * | 2018-05-14 | 2018-08-10 | 黑龙江中医药大学 | A kind of pharmaceutical composition and its preparation method and application prevented and/or treat psoriasis |
| CN115645470A (en) * | 2022-10-18 | 2023-01-31 | 广西科技大学 | Anti-psoriasis extract of datura flower, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1806831B (en) | 2010-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112870236B (en) | Flavone effective part of abelmoschus manihot and preparation method and application thereof | |
| CN104258193A (en) | Drug composition for treating neurasthenia and preventing senile dementia | |
| CN111686147A (en) | Eucommia ulmoides extract and application thereof in treating osteoporosis | |
| CN1267113C (en) | Extract of mulberry twig and its extracting process and novel usage | |
| CN102068478B (en) | Safflower injection and preparation method thereof | |
| CN1806831B (en) | Medicine for treating psoriasis and its preparing process | |
| CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
| CN110669096B (en) | Method for preparing astragaloside from astragalus | |
| CN101474275B (en) | Preparation method and application of Chinese medicine extract for 'prescription for treating diarrhoea with abdominal pain' | |
| CN1895498A (en) | Health-care bee products mixed with Chinese medicines | |
| CN101880301B (en) | Novel method for preparing paeoniflorin extract | |
| CN101638404B (en) | High-purity salvianolic acid B and preparation method and application thereof | |
| CN102648926A (en) | Method for extracting notoginsenoside and notoginseng total amino acid | |
| CN105477126A (en) | Traditional Chinese medicine extract composition used for treating depression and preparation method and application thereof | |
| CN110078667A (en) | A method of extracting huperzine | |
| CN107619427A (en) | A kind of method of the extraction purification rhizoma paridis saponin I from Paris polyphylla | |
| CN101703561A (en) | Eucommia bark effective position for treating osteoporosis and preparation method thereof | |
| CN101249125B (en) | Herbicide composition and its preparation and medicament use | |
| CN107213176B (en) | Hydrangea macrophylla leaf extract, and pharmaceutical composition, preparation method and application thereof | |
| CN101869605B (en) | Method for extracting and separating mulberry leaf flavone and alkaloid composite | |
| CN101259151A (en) | Preparation technique for passionflower total flavones and total saponins without alkaloid and cyanogenic glycoside | |
| CN105079174B (en) | A kind of tonic tablet for kidney-reinforcing and preparation method thereof | |
| CN115364179B (en) | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof | |
| CN105641028A (en) | Process for producing total flavonoids of astragalus membranaceus by utilizing alkaliextraction technology | |
| CN105535080A (en) | Process for producing total flavonoids of radix astragali with microwave technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |